8 July 2020
Corvus starts Phase I trial of immunotherapy to treat Covid-19
Corvus Pharmaceuticals has launched a Phase I clinical trial of its new immunotherapy product, CPI-006, for the treatment of patients with Covid-19.
Focus:
News
-
-
7 July 2020
UK universities launch new Covid-19 drug testing platform
The University of Liverpool's School of Tropical Medicine and Southampton Clinical Trials Unit have launched a Covid-19 drug testing platform called ‘AGILE’.
-
7 July 2020
Annovis Bio gets IRB approval for Phase II trial of ANVS401
Drug platform company Annovis Bio has secured approval from the Central Institutional Review Board (IRB) to conduct a Phase II clinical trial of ANVS401 at 15 sites in the US.
-
7 July 2020
CSL Behring evaluates monoclonal antibody in Covid-19 patients
CSL Behring has started enrolment in a Phase II clinical trial of CSL312 for the treatment of patients with severe respiratory distress caused by Covid-19-related pneumonia.
-
7 July 2020
Immune Regulation and DynPort to trial Covid-19 drug candidate
Biotechnology company Immune Regulation has signed a teaming agreement with DynPort Vaccine to assess ILR201104 as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19 in the...
-
6 July 2020
Brazil’s regulator approves trial of Sinovac’s Covid-19 vaccine
The Brazilian National Regulatory Agency, Anvisa, has given approval to a Phase III clinical trial sponsored by Instituto Butantan to test the efficacy and safety of the inactivated Covid-19 vaccine...
-
6 July 2020
Regeneron launches Phase III Covid-19 prevention trial
Regeneron Pharmaceuticals has started Phase III clinical trials of its double antibody cocktail, REGN-COV2, for the treatment and prevention of Covid-19.
-
6 July 2020
India’s Zydus gets Mexican approval to trial Desidustat for Covid-19
India-based pharmaceutical company Zydus has received approval from the Mexican regulatory authority, COFEPRIS, to assess Desidustat as a potential Covid-19 treatment.
-
6 July 2020
WHO stops hydroxychloroquine and lopinavir/ritonavir trial arms
The World Health Organization (WHO) has decided to discontinue hydroxychloroquine and lopinavir/ritonavir arms in its Solidarity Trial, which is being conducted to assess potential treatments for hospitalised Covid-19 patients.
-
3 July 2020
Abivax doses first patient in Phase II/III Covid-19 clinical trial
French biotechnology company Abivax has dosed the first patient in its Phase II/III study of ABX464 in Covid-19 patients at the University Hospital Center in Nice, France.